What does HER2 status mean for Pancreatic Cancer treatment

HER2 Status in Pancreatic Cancer: What You Need to Know

What HER2 Is

HER2 is a protein that sits on the surface of cells and helps control how cells grow and divide. In some cancers, cells make too much HER2 protein (called "HER2-positive" or "HER2-overexpressing"), which can fuel cancer growth. Understanding your tumor's HER2 status helps doctors decide which treatments might work best for you.

HER2 Status in Pancreatic Cancer: The Key Facts

How common is HER2-positive pancreatic cancer?

HER2-positive pancreatic cancer is relatively rare—only about 1-7% of pancreatic cancers have high HER2 levels. This is important context because HER2 is much more common in breast and stomach cancers, where HER2-targeted treatments have been very successful.

According to recent clinical guidance, when HER2 is found in pancreatic cancer, it's often discovered through proteomics testing (advanced protein analysis) rather than standard genetic testing alone. One remarkable case involved a pancreatic cancer patient with extremely high HER2 levels (nearly 6,000 units—well above the 750-unit threshold for "high expression"). When treated with anti-HER2 therapy, this patient achieved complete remission and survived 180+ weeks—far longer than the typical pancreatic cancer survival of less than one year.

Treatment Options If You're HER2-Positive

FDA-Approved Targeted Therapy:

In 2024, the FDA approved trastuzumab deruxtecan (Enhertu) for HER2-positive advanced solid tumors, including pancreatic cancer. This is an antibody-drug conjugate—essentially a targeted missile that delivers chemotherapy directly to HER2-positive cancer cells.

Important reality check: While Enhertu shows promise, the response rate specifically for pancreatic cancer in clinical trials was modest—only 4% of pancreatic cancer patients showed tumor shrinkage. However, when responses did occur, they lasted an average of 11.8 months, which is meaningful for this aggressive cancer type.

Other HER2-targeted approaches being explored include:

• Dual HER2 blockade (combining two different anti-HER2 drugs)
• Combinations with chemotherapy
• Emerging immunotherapy combinations

Important Considerations for Your Situation

A critical clinical note: According to oncology experts, HER2 is uncommon in KRAS-driven cancers (and KRAS mutations are present in ~87-96% of pancreatic cancers). If your tumor has BOTH a KRAS mutation AND HER2 overexpression, your doctor needs to determine which alteration is actually driving your cancer growth. This matters because it affects which treatment will be most effective.

Questions to Ask Your Oncology Team

1. "Has my tumor been tested for HER2 status?" (This should include both standard immunohistochemistry AND next-generation sequencing or proteomics testing)

2. "If I'm HER2-positive, what evidence supports using HER2-targeted therapy for my specific tumor profile?"

3. "Do I have other mutations (like KRAS) that might be more important to target than HER2?"

4. "Are there clinical trials available for HER2-positive pancreatic cancer, either with Enhertu or other HER2-targeted approaches?"

5. "Should I get proteomics testing in addition to standard genetic testing?" (Proteomics can sometimes identify HER2 overexpression that standard tests might miss)

6. "What is the expected response rate and duration for the treatment you're recommending?"

Key Takeaway

HER2 status is one piece of your tumor's genetic puzzle. While HER2-targeted therapy can produce remarkable responses in some pancreatic cancer patients, it's not effective for everyone. The most important step is ensuring your tumor has been comprehensively tested—including proteomics if available—so your doctor can identify ALL actionable targets and recommend the treatment most likely to help you specifically.

According to ASCO and NCCN guidelines, comprehensive molecular profiling (genetic testing of your tumor) is now recommended for all pancreatic cancer patients at diagnosis. Make sure you have this testing done and keep a copy of the results to share with your care team.

---

Sources:

• CancerPatientLab Webinar: "Novel Therapies and New Directions in Pancreas Cancer, 2024" (Eileen O'Reilly, MD)
• CancerPatientLab Webinar: "Clinical Guidance from Proteomics" (Sheeno Thyparambil)
• Let's Win Pancreatic Cancer: "Treating Cancer By Mutation, Not by Tumor Location"

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.